AlShefa Polyclinic Competitors

MedeAnalytics is redefining how healthcare improves performance. As the healthcare performance improvement company, we help health plans, providers, and employers move beyond analytics and into action—turning data into insight, insight into action, and action into measurable results. Our AI-powered platform unifies data across the healthcare ecosystem and delivers cross-domain intelligence across cost, utilization, quality, risk, network performance, enrollment, and social determinants of health (SDOH). We surface what matters most, prioritize opportunities by impact and ROI, and ensure execution through workflows, playbooks, and accountability. We are a market leader in improving Employer Group Performance for commercial health plans—helping drive client retention, broker confidence, and better outcomes—while also improving performance across Medicare Advantage and Medicaid populations. We don’t just provide analytics. We prioritize and power performance—improving MLR, reducing admin cost, increasing ROI, and helping ensure the right care happens across populations.

Central California's leading Home Health, Hospice, and In Home Care Agency; providing world-class, personalized medical services in the privacy and comfort of your home. (Established in 2003).

Careplus (M) Sdn Bhd was incorporated in Malaysia on 30 March 2010 as a private limited company under the name of Careplus Group Sdn. Bhd. Subsequently, on 5 April 2010, we converted our status from a private limited company to a public limited company to facilitate our listing on the ACE Market of Bursa Securities. We are principally an investment holding company whilst our subsidiaries are involved in the manufacturing, processing and trading of gloves. Careplus has also on 5 February 2020 entered into a joint venture arrangement with Ansell Services (Asia) Sdn. Bhd. (“Ansell”) for the disposal, via a conditional SPA entered into between Careplus and Ansell, of 50% equity interest in Careplus (M) Sdn. Bhd. (“CMSB”), consisting of 14,550,000 ordinary shares in CMSB for a disposal consideration of approximately RM26.97 million, to be satisfied entirely by cash (“Disposal”). Upon completion of the Disposal and in accordance with the terms of the Shareholders’ Agreement entered into between Careplus, Ansell and CMSB, CMSB ceased to be a wholly-owned subsidiary of Careplus and became a 50% of joint venture of Careplus.